Education
About Us
Working with TipRanks
Follow Us
CSL Limited (CSLLY)
OTHER OTC:CSLLY
Top Page
CSL
(OTC:CSLLY)
Select Model
Select Model
Rating:70Outperform
Price Target:
$74.00
▲(13.08% Upside)
CSL Limited's overall stock score of 70 reflects its strong financial performance and strategic initiatives highlighted in the earnings call, which are offset by bearish technical indicators and moderate valuation metrics. The company's robust financial health and transformative strategies position it well for future growth, but current market momentum suggests caution.
CSL (CSLLY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$63.40B
Dividend Yield2.17%
Average Volume (3M)99.70K
Price to Earnings (P/E)21.1
Beta (1Y)0.47
Revenue Growth5.08%
EPS Growth13.41%
CountryUS
Employees32,698
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.03
Shares Outstanding970,302,800
10 Day Avg. Volume44,397
30 Day Avg. Volume99,703
Financial Highlights & Ratios
PEG Ratio1.91
Price to Book (P/B)3.97
Price to Sales (P/S)4.97
P/FCF Ratio30.14
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue5.67
Enterprise Value/Gross Profit11.49
Enterprise Value/Ebitda16.77
Forecast
1Y Price Target
$99.00Price Target Upside51.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
CSL Business Overview & Revenue Model
Company DescriptionCSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
How the Company Makes MoneyCSL Limited generates revenue primarily through the sale of its biotherapeutic and vaccine products. Its major revenue streams include plasma-derived therapies such as immunoglobulins, albumin, and coagulation factors that treat conditions like hemophilia and immune deficiencies. Additionally, its Seqirus segment contributes significantly to revenue through the production and distribution of influenza vaccines. The company benefits from strategic partnerships and collaborations that enhance its research and development capabilities, allowing it to innovate and expand its product offerings. CSL's earnings are also influenced by its extensive global distribution network and its ability to leverage economies of scale in manufacturing.
CSL Earnings Call Summary
Earnings Call Date:Aug 18, 2025
(Q4-2025)
| % Change Since: |
Next Earnings Date:Feb 10, 2026
Earnings Call Sentiment Neutral
CSL demonstrated solid revenue and profit growth, introduced transformative corporate strategies including a demerger and share buyback, and achieved operational efficiencies. However, challenges in Seqirus revenue growth, impacts from U.S. healthcare reforms, and the need for significant cost reductions in R&D and plasma centers indicate some operational pressures.Q4-2025 Updates
Positive Updates
Overall Revenue and Profit Growth
CSL Group revenue grew by 5% on a constant currency basis. NPATA increased by 14% and NPAT grew by 17%.
Dividend Increase
Final dividend increased by 12% to USD 1.62 per share.
Free Cash Flow Improvement
Free cash flow increased by 58%.
Plasma Yield Improvements
Yield improvements are ahead of plan, leading to increased efficiency in plasma collection.
Demerger of CSL Seqirus
Announced intent to demerge CSL Seqirus as an independent ASX-listed entity by fiscal year 2026.
Share Buyback Program
Introduction of a multiyear share buyback program starting with AUD 750 million in FY '26.
Strong Market Leadership in Hemophilia
CSL's hemophilia franchise demonstrated market leadership with growth of 13% at constant currency.
Negative Updates
Seqirus Revenue Growth Challenges
Revenue for CSL Seqirus was up only 2%, with challenges due to declining vaccination rates and competitive pressures.
Impact of U.S. Part D Reform
Impact from the U.S. Medicare Part D reform affected revenue growth for Ig products.
Pressure on Gross Margins
CSL Behring's gross margin target timeframe removed due to FX headwinds, product mix challenges, and fixed cost absorption issues.
R&D Output Concerns
R&D output has not met expectations, leading to strategic changes and cost reductions.
Underperforming Plasma Centers
Closure of 22 underperforming plasma centers due to inefficiencies and cost challenges.
Company Guidance
In the CSL Limited Full Year Financial Results call for Fiscal Year 2025, the company reported several key financial metrics and provided guidance for Fiscal Year 2026. The CSL Group achieved a 5% revenue growth on a constant currency basis, with NPATA increasing by 14% and NPAT by 17%. Leverage improved to 1.8x net debt-to-EBITDA, and free cash flow rose by 58%. The final dividend was increased by 12% to USD 1.62 per share. CSL announced major transformational changes expected to yield over USD 0.5 billion in savings by the end of Fiscal Year 2028, with plans to reinvest these savings in high-priority opportunities. Additionally, the company intends to demerge CSL Seqirus as an independent ASX-listed entity in Fiscal Year 2026. For Fiscal Year 2026, CSL anticipates revenue growth of approximately 4% to 5% and NPATA growth of 7% to 10% at constant currency, excluding restructuring costs.CSL Financial Statement Overview
Summary
CSL exhibits a solid financial profile with consistent revenue growth, strong profitability, and efficient cash flow management. The company's moderate leverage and healthy return on equity further enhance its financial stability. While there are minor concerns regarding increasing debt levels and cost pressures, CSL's overall financial health remains robust, positioning it well for future growth.Income Statement
CSL has demonstrated consistent revenue growth, with a notable increase of 5.0% in the latest year. The company maintains strong profitability, evidenced by a gross profit margin of 51.5% and a net profit margin of 19.5%. EBIT and EBITDA margins are robust at 26.7% and 33.3%, respectively, indicating efficient operations. However, the slight decline in gross profit margin over the years suggests potential cost pressures.85
Very Positive
Balance Sheet
The balance sheet reflects a stable financial position with a debt-to-equity ratio of 0.59, indicating moderate leverage. Return on equity is healthy at 15.5%, showcasing effective use of equity capital. The equity ratio stands at 49.0%, suggesting a solid equity base. However, the gradual increase in total debt over the years warrants monitoring.78
Positive
Cash Flow
CSL's cash flow performance is strong, with a free cash flow growth rate of 35.6% in the latest year, highlighting improved cash generation. The operating cash flow to net income ratio of 0.74 and free cash flow to net income ratio of 0.71 indicate efficient cash conversion. Despite fluctuations in free cash flow growth in previous years, the recent trend is positive.82
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.47B | 15.43B | 14.80B | 13.17B | 10.49B | 10.27B |
| Gross Profit | 7.64B | 7.95B | 7.56B | 6.71B | 5.66B | 5.74B |
| EBITDA | 5.23B | 5.13B | 4.73B | 3.90B | 3.46B | 3.63B |
| Net Income | 3.04B | 3.00B | 2.64B | 2.19B | 2.25B | 1.78B |
Balance Sheet | ||||||
| Total Assets | 39.54B | 39.40B | 38.02B | 36.23B | 28.35B | 13.63B |
| Cash, Cash Equivalents and Short-Term Investments | 2.16B | 2.16B | 1.66B | 1.55B | 10.44B | 1.36B |
| Total Debt | 11.54B | 11.50B | 12.18B | 12.23B | 9.66B | 4.36B |
| Total Liabilities | 18.06B | 18.00B | 18.62B | 18.41B | 13.77B | 7.34B |
| Stockholders Equity | 19.40B | 19.34B | 17.36B | 15.79B | 14.58B | 6.29B |
Cash Flow | ||||||
| Free Cash Flow | 3.04B | 2.54B | 1.51B | 909.00M | 1.38B | 2.43B |
| Operating Cash Flow | 3.70B | 3.56B | 2.76B | 2.60B | 2.63B | 3.62B |
| Investing Cash Flow | -882.99M | -850.00M | -1.26B | -11.84B | -1.64B | -1.67B |
| Financing Cash Flow | -2.33B | -2.24B | -1.28B | 456.00M | 7.68B | -1.40B |
CSL Technical Analysis
Negative
65.44
Price Trends
77.27
Negative
77.62
Negative
79.70
Negative
Market Momentum
-2.99
Negative
29.79
Positive
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSLLY, the sentiment is Negative. The current price of 65.44 is below the 20-day moving average (MA) of 68.18, below the 50-day MA of 77.27, and below the 200-day MA of 79.70, indicating a bearish trend. The MACD of -2.99 indicates Negative momentum. The RSI at 29.79 is Positive, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CSLLY.
CSL Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | 98.23B | 27.38 | 21.18% | ― | 10.38% | 0.00% | |
75 Outperform | 62.74B | 14.92 | 14.89% | 0.45% | 5.38% | 3.58% | |
74 Outperform | 44.89B | 34.61 | 15.15% | ― | 89.58% | 0.00% | |
70 Outperform | $63.40B | 21.14 | 16.36% | 2.17% | 5.08% | 13.41% | |
60 Neutral | 59.45B | -183.85 | -127.33% | ― | 5.01% | -330.09% | |
49 Neutral | 23.13B | -60.76 | -1.88% | ― | 7.51% | 30.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
CSLLY
CSL
65.44
-32.08
-32.90%
ALNY
Alnylam Pharma
453.56
181.73
66.85%
REGN
Regeneron
591.99
-495.33
-45.56%
VRTX
Vertex Pharmaceuticals
383.12
-76.88
-16.71%
ARGX
Argenx Se
736.76
208.26
39.41%
BNTX
BioNTech SE
96.22
-16.83
-14.89%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.